Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026

Cellectis held its general shareholders meeting in Paris on June 25, 2026, with about 55.84% of voting rights represented. According to the company, resolutions 1–29 were adopted and resolution 30 was rejected, in line with the board’s recommendations. Voting results and resolution details are posted on Cellectis’ website.

Original reporting
Published Jun 25, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 25, 2026, 9:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026 — source image
Decision brief

The 30-second read

$CLLSNeutralLow
01

Why it matters

Because the text does not specify what resolution 30 covered, the trading implication is uncertain; it is primarily a governance/process update unless resolution 30 is material.

02

Market read

Routine shareholder-meeting vote results; potential impact depends entirely on the substance of the rejected resolution 30, which is not described here.

03

What to watch

Traders should check the linked Cellectis results page for the exact wording of resolution 30 to determine whether it changes financing, strategy, or governance in a way that could affect valuation.

Relevance 4/10Novelty 3/10Timing: after-hours / same-day post-meeting governance update (June 25, 2026)

Background

The article reports results from Cellectis’ shareholders general meeting held June 25, 2026, including adoption/rejection of numbered resolutions.

Company-level read

Ticker impact

$CLLSNeutralLow confidence
Context

Cellectis held its June 25, 2026 shareholders meeting and reported resolutions 1–29 adopted while resolution 30 was rejected.

Expected impact

Likely limited near-term impact unless resolution 30 relates to a material corporate action; otherwise treat as routine governance update.

Evidence & confidence

The disclosure is specific (adopted vs rejected) but lacks the substance of resolution 30, so traders cannot map it to a clear financial catalyst.

Market effects

Minimal read-across for gene-editing biotechs; this is company-specific governance reporting without clinical/financing updates.

No clear regional spillover; event is in Paris with Nasdaq/Euronext listings.

Low global relevance; no new regulatory, trial, or deal information.

Counterpoint

If resolution 30 concerned a material item (e.g., capital structure, board changes, or major authorization), the market reaction could be larger than implied by the generic vote summary.

Key entities

  • Cellectis

    Clinical-stage gene-editing biotechnology company listed on Nasdaq (CLLS) and Euronext Growth (ALCLS).

  • Shareholders general meeting (June 25, 2026)

    Voting event where resolutions 1–29 were adopted and resolution 30 was rejected.

Related articles

$CLLSMedAI 8/10

Cellectis Earnings Call Highlights In Vivo Editing Shift

Cellectis (CLLS) reported Q3 earnings, highlighting a shift to in vivo gene editing. Preclinical results for HEAL-101 and HEAL-201 showed promise, with HEAL-101 reducing APOC3 levels by 67% and triglycerides by 76% in mice. The company expects clinical data in 2027-2028. Revenue fell to $19.9M, but net income improved to a $5.2M gain. Cash runway extends into 2H 2028. Management also announced workforce reductions and discontinued legacy programs.

$CLLSMed

Cellectis SA (CLLS) (Q3 2026) Earnings Call Highlights: Strategic Shift to Gene

Cellectis SA (CLLS) discussed its strategic shift to gene editing during its Q3 2026 earnings call. Management highlighted the selection of APOC3 over ANGPTL3 for triglyceride reduction, with plans to start Phase 1 dosing by end-2027. The company reported $149M in cash as of September 30, 2026, with a runway into H2 2028. Revenue decreased to $19.9M from $67.4M YoY, while R&D expenses increased to $108.8M from $69.1M, driven by the AstraZeneca collaboration.

$CLLSMed

What Cellectis (CLLS) Said on Its Q3 Earnings Call

Cellectis (CLLS) reported Q3 earnings, highlighting HEAL-201's potential in reducing PCSK9 levels and plans for a Phase 1 trial. The company expects to cut global headcount by up to 70% in 2026-2027. Revenues fell to $19.9M from $67.4M YoY, while R&D expenses rose to $108.8M. Cash reserves were $149M as of Sept. 30, down from $211M at the end of 2025.

$CLLSMedAI 8/10

Cellectis Reports Third-Quarter 2026 Results and In Vivo Editing Data

Cellectis SA reported Q3 2026 results with $149M in cash, $19.9M revenue (down from $67.4M), and increased R&D expenses to $108.8M. Preclinical data showed promising results for .HEAL-101 and .HEAL-201. The company is shifting focus to in vivo gene editing, discontinuing lasme-cel and eti-cel programs. Analysts rate CLLS stock as Buy with $8.00 target, while TipRanks' AI rates it Neutral.